RareMed Solutions Expands Relationship with PTC Therapeutics

RareMed Solutions, a provider of patient support services for complex therapies, is expanding its relationship with PTC Therapeutics with the launch of non-commercial pharmacy dispensing services for PTC’s therapy, Sephience.

The recent approval of Sephience by the FDA marks a significant milestone in the treatment of phenylketonuria (PKU) for both adult and pediatric patients. This new therapy, developed by PTC, has the potential to transform the lives of those living with PKU by offering a treatment option that addresses their unique needs.

RareMed will be providing non-commercial pharmacy dispensing services to support patients in challenging circumstances. These services are designed to provide both patients and healthcare providers with appropriate assistance.

To provide seamless access and support, RareMed RareSupport Team is expanding. A larger team of liaisons will play a crucial role in providing outreach and coordination efforts across PTC’s supported therapies so that every patient may receive appropriate, personalized care and attention, while leadership will provide guidance, oversight, and compliance support.

The program’s support framework is designed to assist patients and providers alike in navigating the treatment landscape with confidence. By expanding the team, RareMed aims to facilitate a smoother, more coordinated experience for all stakeholders involved in the treatment process.